Metabolic Flexibility
Fits patients focused on glucose-handling biology, insulin-sensitivity goals, low energy, poor metabolic flexibility, or healthy-aging mitochondrial support.
Mitochondrial - Metabolic - Visceral Fat Support
The MOTS-c + Tesamorelin stack is designed for patients whose goals include metabolic optimization, visceral-fat reduction, mitochondrial function, insulin-sensitivity biology, body composition, liver-fat metabolism, and recovery capacity. This stack combines mitochondrial signaling support with growth-hormone-releasing hormone pathway support for a more complete metabolic strategy.
Overview
This stack combines two different metabolic pathways. MOTS-c supports mitochondrial signaling, metabolic flexibility, AMPK-related energy pathways, insulin-sensitivity biology, and exercise-response signaling. Tesamorelin supports the growth-hormone-releasing hormone pathway, increasing endogenous growth-hormone signaling tied to visceral-fat metabolism, IGF-1 activity, body composition, and recovery capacity.
IPS evaluates consultation goals, health history, medications, labs when available, endocrine history, glucose status, body-composition goals, contraindications, and provider judgment before considering this protocol.
Ideal for
The MOTS-c + Tesamorelin stack is designed for patients whose metabolic goals involve mitochondrial function, insulin signaling, visceral fat, liver-fat metabolism, body composition, and recovery capacity.
Fits patients focused on glucose-handling biology, insulin-sensitivity goals, low energy, poor metabolic flexibility, or healthy-aging mitochondrial support.
Fits patients with visceral-fat, central body-composition, liver-fat metabolism, lean-tissue preservation, or fat-loss phase goals.
Fits patients who need metabolic support beyond appetite suppression alone, paired with training, nutrition, protein intake, sleep, and walking or zone-2 conditioning.
The science
The MOTS-c + Tesamorelin stack combines mitochondrial signaling support with growth-hormone-releasing hormone pathway support.
MOTS-c is a mitochondrial-derived peptide encoded by the mitochondrial genome. It is composed of 16 amino acids and is used as part of clinician-guided planning for metabolic homeostasis, cellular stress adaptation, insulin-sensitivity biology, glucose metabolism, exercise-response signaling, and AMPK-related energy pathways.
MOTS-c is often described as an exercise-associated mitochondrial peptide because it is linked to skeletal-muscle metabolism and cellular adaptation under metabolic stress. It supports metabolic flexibility by influencing pathways involved in energy sensing, glucose utilization, mitochondrial communication, and inflammation-related metabolic signaling.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, also called GHRH or GRF. It acts on the anterior pituitary to stimulate endogenous growth-hormone secretion. Growth-hormone and IGF-1 signaling are tied to lipolysis, visceral-fat metabolism, lean-tissue support, recovery capacity, and metabolic regulation.
Tesamorelin is best known for its role in abdominal-fat reduction in a specific FDA-approved context. At IPS, Tesamorelin is discussed more broadly as a GHRH-pathway peptide tied to visceral-fat, body-composition, and metabolic-health goals when medically appropriate. MOTS-c is not FDA-approved and is presented by IPS as investigational and informational mitochondrial peptide content.
MOTS-c supports mitochondrial energy signaling and metabolic flexibility, while Tesamorelin supports endogenous GH/IGF-1 pathway activity tied to visceral-fat metabolism and body composition.
Dual how it works
This stack supports metabolic optimization through two complementary systems: mitochondrial energy signaling and growth-hormone-releasing hormone pathway activation.
MOTS-c supports mitochondrial-to-nuclear signaling, AMPK-related energy pathways, metabolic flexibility, glucose utilization, insulin-sensitivity biology, and exercise-response adaptation.
Tesamorelin supports the growth-hormone-releasing hormone pathway by signaling the pituitary to release endogenous growth hormone. This supports downstream IGF-1 activity, lipolysis, visceral-fat metabolism, and recovery signaling.
Together, MOTS-c and Tesamorelin support energy metabolism, fat metabolism, glucose handling, body-composition goals, lean-tissue preservation, and recovery capacity through complementary pathways.
Clinical benefits
MOTS-c supports mitochondrial signaling, energy regulation, cellular stress adaptation, and metabolic flexibility.
MOTS-c supports glucose-handling and insulin-sensitivity pathways, especially when paired with nutrition, training, and lifestyle structure.
Tesamorelin supports endogenous GH/IGF-1 signaling tied to lipolysis and visceral-fat metabolism.
This stack supports fat-loss phases, body-composition goals, lean-tissue preservation, and metabolic optimization.
This stack supports metabolic-health goals involving liver-fat metabolism and central adiposity patterns.
MOTS-c supports exercise-response biology, skeletal-muscle metabolism, and metabolic adaptation.
Tesamorelin supports GH-pathway signaling tied to recovery, tissue repair, sleep quality, and resilience.
MOTS-c and Tesamorelin both fit healthy-aging protocols focused on mitochondrial function, metabolic resilience, body composition, and recovery capacity.
IPS use
IPS uses the MOTS-c + Tesamorelin stack as an advanced metabolic optimization protocol when the patient's goals involve visceral fat, body composition, insulin signaling, mitochondrial function, metabolic flexibility, and recovery capacity.
IPS evaluates health history, medication use, metabolic goals, body-composition history, glucose status, lab history when available, endocrine history, contraindications, digestive tolerance, and overall candidacy before considering this protocol. IPS evaluates health history, medication use, metabolic goals, body-composition history, glucose status, lab history when available, endocrine history, contraindications, digestive tolerance, and overall candidacy before considering this protocol.
This stack can be paired with nutrition strategy, protein intake, resistance training, walking or zone-2 conditioning, sleep optimization, hydration, glucose monitoring when appropriate, liver-support strategies, and other IPS metabolic protocols when clinically appropriate.
Safety & candidacy
This stack requires medical review because it affects mitochondrial signaling, glucose-handling pathways, growth-hormone signaling, IGF-1 activity, and body-composition physiology. IPS evaluates health history, medication use, glucose status, diabetes history, cancer history, thyroid history, edema history, carpal tunnel symptoms, pregnancy or nursing status, liver history, sleep history, athlete-testing concerns, and contraindications before considering this protocol.
Questions
MOTS-c + Tesamorelin is a metabolic optimization stack designed to support mitochondrial function, metabolic flexibility, insulin-sensitivity biology, visceral-fat metabolism, body composition, and recovery capacity.
MOTS-c is a mitochondrial-derived peptide that supports mitochondrial signaling, AMPK-related energy pathways, glucose utilization, insulin-sensitivity biology, exercise-response adaptation, and metabolic flexibility.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone. It signals the pituitary to support endogenous growth-hormone release, which is tied to IGF-1 activity, lipolysis, visceral-fat metabolism, lean-tissue support, and recovery capacity.
They support different metabolic pathways. MOTS-c supports mitochondrial energy signaling and metabolic flexibility. Tesamorelin supports GH/IGF-1 signaling and visceral-fat metabolism. Together they create a broader body-composition and metabolic optimization strategy.
No. GLP-1 medications primarily target appetite, satiety, gastric emptying, and glucose regulation. MOTS-c + Tesamorelin is positioned around mitochondrial function, metabolic flexibility, visceral-fat metabolism, GH-pathway signaling, and body composition.
Tesamorelin is best known for its role in abdominal-fat reduction in a specific FDA-approved context. At IPS, Tesamorelin is discussed more broadly as a GHRH-pathway peptide tied to visceral-fat, body-composition, and metabolic-health goals when medically appropriate.
Yes. This stack should be paired with nutrition strategy, protein intake, resistance training, walking or zone-2 conditioning, hydration, sleep optimization, glucose monitoring when appropriate, and long-term behavior change.
In some cases, metabolic protocols can be layered, but this requires medical review. IPS evaluates medications, appetite, digestion, glucose response, lean-tissue preservation, side effects, and the overall goal before combining strategies.
This stack may not be appropriate for patients with certain cancer history, active malignancy concerns, uncontrolled diabetes or glucose instability, significant endocrine disorders, pregnancy or nursing status, medication-related contraindications, or concerns related to GH/IGF-1 signaling. Medical review is required.
Athletes subject to WADA, NCAA, professional league, military, or organizational testing should review applicable rules before starting any peptide protocol.
Why IPS is different
Many consumers encounter products online labeled for research use only, not for human consumption, or laboratory chemicals. Those labels matter because they are not intended for patient care.
A product mixed at home from an online powder and labeled research use only is fundamentally different from care that begins with consultation, provider review, appropriate prescribing, and ongoing clinical guidance.
Annual Membership
12-month IPS members receive access to preferred pricing on eligible peptide programs after consultation and medical review.
Consultation
Review your body-composition, metabolic, visceral-fat, liver-fat, and recovery goals with IPS to determine whether MOTS-c + Tesamorelin is appropriate.